ImmPACT Bio is a clinical-stage company based in Los Angeles developing logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for cancer and autoimmune diseases. Its lead autoimmune candidate, IMPT-514, is a CD19/CD20 bispecific CAR T-cell therapy designed to deeply deplete autoreactive B cells as a one-time treatment with the potential to replace chronic immune suppression. IMPT-514 shares the same CAR construct as IMPT-314, which is under development for certain non‑Hodgkin's lymphomas. The company is evaluating IMPT-514 in an open-label Phase 1b/2 dose-escalation trial in refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE), with initial efficacy and safety data expected in the second half of 2024. IMPT-514 has received FDA Fast Track designation for active and refractory LN and SLE, and preclinical work showed efficient manufacture from heavily immunosuppressed patients, potent autologous B-cell elimination, and a moderate cytokine profile. In February 2024 ImmPACT Bio was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the ongoing Phase 1b/2 development of IMPT-514. ImmPACT Bio is a clinical-stage company developing logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Led by president and CEO Sumant Ramachandra, M.D., Ph.D., MBA, the company focuses on CAR T platforms designed to prevent antigen escape and reduce on-target off-tumor toxicities. Its technologies also aim to overcome the immunosuppressive tumor microenvironment. The company’s technology is based on work by Yvonne Chen and Antoni Ribas at UCLA and Gideon Gross at the MIGAL‑Galilee Research Institute. ImmPACT intends to use newly raised funds to expand the curative potential of cell therapies and to address biological challenges that have limited efficacy in hard-to-treat tumor types. The company is based in Camarillo, California and is at the clinical stage of development. ImmPACT Bio USA is a Camarillo, California–based company, founded out of the FutuRx incubator in Ness Ziona, Israel, developing novel engineered T-cell therapies for cancer. Its lead programs focus on targeting loss of genes in solid tumors using engineered T cells. The company was founded based on insights from Prof. Gideon Gross (Migal Research Institute), who collaborated with Prof. Zelig Eshhar on early CAR T technologies, and is led by CEO Rick Kendall, Ph.D. ImmPACT is advancing a set of engineered T-cell therapeutics rather than traditional CAR T constructs. The company closed a Series A equity financing in 2020 to support its development efforts. No operating metrics were disclosed in the article.

Total raised

$137M

Funding rounds

3

Latest round

Grant

Latest activity

Feb 2024